Over the course of the last decade it has become apparent that nitric oxide and other small redox-reactive molecules promote the progression of human cancers. Our research goals are focused on the identification of redox-related mechanisms and biomarkers expressed during chronic inflammation as it relates to cancer progression and poor clinical outcome. We are ultimately interested in using redox-specific mechanistic information to develop agents that target pro-tumor pathways for improved clinical outcome.